Wednesday, August 06, 2025 9:57:06 AM
This one caught my eye for a bottom play. Almost there.
Looks like this company is CRUSHING it. lmao
AIM daily
Like your post.
Looks like this company is CRUSHING it. lmao
AIM daily
Like your post.
Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?
"We hope not." Richard Dennis
Recent AIM News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 03:31:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/21/2026 03:30:19 PM
- AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement • GlobeNewswire Inc. • 05/20/2026 07:02:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/19/2026 09:20:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 12:03:26 PM
- AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities • GlobeNewswire Inc. • 05/19/2026 12:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:45:38 PM
- AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer • GlobeNewswire Inc. • 05/14/2026 12:41:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/12/2026 08:30:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 08:27:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:50:03 PM
- AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds • GlobeNewswire Inc. • 05/08/2026 12:40:00 PM
- AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential • GlobeNewswire Inc. • 05/07/2026 12:23:00 PM
- AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP • GlobeNewswire Inc. • 04/16/2026 01:00:00 PM
- AIM ImmunoTech Provides Routine Update on Annual Filings • GlobeNewswire Inc. • 04/13/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:33:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/10/2026 08:30:41 PM
- AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event • GlobeNewswire Inc. • 04/09/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 09:30:45 PM
- AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors • GlobeNewswire Inc. • 03/18/2026 12:36:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:30:12 PM
- AIM ImmunoTech Announces Closing of its Rights Offering • GlobeNewswire Inc. • 03/07/2026 12:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 10:15:32 PM
